Prescribing Hydroxyzine

Why Hydroxyzine Matters

Hydroxyzine occupies a peculiar and useful niche: it is a first-generation antihistamine, in continuous use since the 1950s, that happens to carry a genuine FDA indication for anxiety. In an era where the acute-anxiety conversation collapses almost immediately into "benzodiazepine or not," hydroxyzine is the most important third option: a fast-acting, PRN-friendly agent with no abuse potential, no dependence, no tolerance, no withdrawal syndrome, and no DEA schedule. You can hand it to a patient with a substance use history, an addiction-medicine referral in their chart, or a hard "no controlled substances" line in your practice policy, and still give them something that works within the hour.

That is the case for hydroxyzine. The case against it is equally concrete and lives in one word: anticholinergic. Hydroxyzine is sedating and dries everything out (mouth, eyes, bladder, bowel), and in the wrong patient (older, cognitively fragile, polypharmacy, cardiac) that burden ranges from annoying to genuinely harmful. It sits on the Beers list for exactly this reason. It can prolong the QT interval. So the drug is neither a benign OTC-grade sleep aid nor a benzodiazepine substitute you can prescribe without thought: it is a specific tool with a specific tradeoff.

A note on terminology: Vistaril is hydroxyzine pamoate; Atarax is hydroxyzine hydrochloride (HCl). These are two salts of the same molecule and are clinically interchangeable milligram-for-milligram for psychiatric purposes. The pamoate salt was historically marketed as the "anxiety" product and the HCl as the "antihistamine/pruritus" product, but that split is marketing, not pharmacology. Prescribe whichever your patient's formulary favors.

Part 1: Indications: Who Is Hydroxyzine For?

FDA-Approved Uses

• Anxiety: symptomatic relief of anxiety and tension associated with psychoneurosis, and as an adjunct in organic disease states with anxiety. (This is a genuine, old-school anxiety indication; hydroxyzine is one of the few non-benzodiazepine, non-antidepressant agents that carries one.)
• Pruritus: allergic and histamine-mediated itch (its dermatologic home turf).
• Pre/postoperative sedation and as an adjunct to control emesis and anxiety perioperatively (the intramuscular form).

Note that insomnia is not a formal FDA indication, but hydroxyzine is widely and reasonably used off-label for sleep: its sedating antihistamine action is exactly what makes daytime use difficult and nighttime use useful.

The Evidence-Based Clinical Uses

Generalized anxiety disorder (GAD). This is hydroxyzine's most defensible psychiatric use. Several randomized controlled trials and a Cochrane review support efficacy in GAD, with effect sizes broadly comparable to buspirone and, in some trials, approaching benzodiazepines over short courses. It is not a first-line agent (SSRIs/SNRIs remain first-line for chronic GAD), but it is a reasonable monotherapy or adjunct, and a genuinely useful bridge during the 2 to 6 weeks it takes an SSRI to work.

Acute/situational anxiety, PRN. This is where hydroxyzine earns its keep in real-world practice. Onset is roughly 15 to 30 minutes, peak effect around 2 hours, and the half-life (about 20 hours in adults; longer in the elderly) means a single dose covers most of a day. For the patient who needs something to take before a flight, a medical procedure, a panic-provoking situation, or during an SSRI ramp-up, and for whom a benzodiazepine is unwise or unwanted, hydroxyzine is the cleanest PRN option available.

Situational and short-term insomnia. Off-label but common and sensible. The sedation that limits daytime dosing is the therapeutic effect at night.

Adjunctive use during benzodiazepine tapers or in patients with SUD. Because it carries no reinforcement, tolerance, or withdrawal, hydroxyzine is a workhorse for anxiety in patients you cannot or will not give a controlled substance: active or historical substance use disorder, diversion concerns, or a practice policy against benzodiazepines. It belongs in the algorithm for the anxious patient who has rotated through SSRIs/SNRIs and for whom benzodiazepine sedation and dependence are the problem.

Where Hydroxyzine Is Not the Answer

• Panic disorder and social anxiety disorder: no meaningful evidence base; use SSRIs/SNRIs.
• OCD, PTSD: not a treatment.
• Chronic, around-the-clock anxiety in older or medically complex patients: the anticholinergic burden accumulates and the risk/benefit turns against you (see Special Populations).
• As a long-term nightly hypnotic: tolerance to the sedative effect can develop even though there is no dependence, and chronic anticholinergic exposure is undesirable.

Part 2: Mechanism: Why It Works, and Why It Costs What It Costs

Hydroxyzine is a piperazine first-generation H1 antihistamine. Its clinically relevant actions:

• H1-receptor antagonism (central and peripheral). The central H1 blockade produces sedation and the anxiolytic/calming effect; peripheral H1 blockade produces the antihistaminic/antipruritic effect. Because it is lipophilic and readily crosses the blood-brain barrier (unlike second-generation antihistamines such as cetirizine, which is, notably, a metabolite of hydroxyzine but far less sedating), it is a centrally active antihistamine. That CNS penetration is the whole point for anxiety and the whole problem for daytime alertness.
• Anticholinergic (antimuscarinic) activity. Hydroxyzine has meaningful muscarinic antagonism, which drives dry mouth, constipation, urinary retention, blurred vision (mydriasis/cycloplegia), tachycardia, and, centrally, confusion and delirium risk, especially in the elderly. This is the source of nearly every problematic side effect and its Beers-list status.
• Weak 5-HT2A antagonism and other minor receptor activity. Contributes modestly to the anxiolytic/sedative profile; not a primary driver.
• hERG potassium-channel effect leading to QT prolongation. Like several antihistamines, hydroxyzine can prolong the QTc, which is the basis of the cardiac cautions below.

Pharmacokinetics You Can Use

The relatively long half-life is worth internalizing: a PRN dose is not gone in three hours. Repeated daytime dosing stacks, and in the elderly the parent drug lingers well over a day, which is exactly why cumulative sedation and confusion sneak up on you.

Part 3: How to Start and Dose

Hydroxyzine has a wide, forgiving dosing range and no serum-level monitoring, a refreshing contrast to lithium. You titrate to effect and tolerability.

For Anxiety

• Typical dose: 25–50 mg per dose.
• Frequency: up to four times daily (QID) for the FDA anxiety indication, i.e., 25–100 mg QID is the labeled ceiling, though most outpatients live far below this.
• Practical outpatient approach: start 25 mg and see how sedating it is for that individual before going higher. Many patients do well with 25–50 mg once or twice daily or PRN.
• PRN dosing: 25–50 mg taken 15 to 30 minutes before an anticipated anxiety trigger, or at symptom onset. Counsel that it takes about 30 minutes and peaks at about 2 hours; it is not instantaneous, and re-dosing too quickly just stacks sedation and dry mouth.

For Insomnia (Off-Label)

• 25–50 mg at bedtime is the usual range; up to about 100 mg QHS in some patients, but the anticholinergic hangover and next-day grogginess climb with dose.
• Start at 25 mg QHS and titrate only if needed. Higher is not clearly better for sleep and is clearly worse for dry mouth and morning fog.

For Pruritus (Context)

25 mg TID to QID is typical; sedation is often the dose-limiting factor here too.

Titration Principles

• There is no need for a slow multi-week titration as with an SSRI. The main thing you are titrating against is sedation: find the dose that calms without flattening.
• Start low in anyone older, smaller, hepatically impaired, or on other sedating/anticholinergic drugs. For frail elderly patients, if you use it at all, 12.5–25 mg is a more appropriate starting and often maximum dose.
• No taper is required to stop (see Discontinuation): a genuine convenience.

Formulations

Oral tablets/capsules and oral suspension; IM injection (do not give IV; tissue/vascular irritation and hemolysis have been reported). Vistaril = pamoate; Atarax = HCl; equivalent for anxiety.

Part 4: Monitoring

Hydroxyzine's monitoring burden is refreshingly light: there are no required routine labs, no serum levels, no renal or thyroid surveillance. What you do monitor is clinical and cardiac.

At Baseline / Before Starting

• Screen for QT-prolonging risk factors in anyone you have reason to worry about: personal or family history of long QT / syncope / arrhythmia, other QT-prolonging medications, bradycardia, and electrolyte abnormalities (low potassium, low magnesium). Consider a baseline ECG in older patients, cardiac patients, or those already on QT-prolonging drugs, not universally, but with a low threshold.
• Tally the total anticholinergic burden: what else is the patient taking that dries them out or clouds cognition (TCAs, oxybutynin, diphenhydramine, benztropine, paroxetine, many antipsychotics)? Hydroxyzine adds to all of it.

During Treatment

• Sedation and cognition, especially in the first days and especially in older patients.
• Anticholinergic symptoms: dry mouth, constipation, urinary hesitancy/retention, blurred vision, and (a red flag in the elderly) new confusion.
• Falls: the sedation-plus-orthostasis combination is a fall risk in older adults.
• Correct electrolytes (K⁺, Mg²⁺) if the patient develops a reason for them to drop (vomiting, diuretics, poor intake), since hypokalemia/hypomagnesemia amplify QT risk.

That is the entire monitoring program. The contrast with lithium or clozapine is the point: hydroxyzine's safety management is mostly patient selection done up front, not lab surveillance done over time.

Part 5: Side Effects and How to Manage Them

Sedation / Drowsiness

The signature effect. Intended when dosing for sleep or acute distress; limiting for daytime anxiety use.

• Dose timing: push daytime doses to the evening where possible; reserve the bulk of the dose for bedtime.
• Lower the dose: sedation is dose-related.
• Warn about driving and machinery, particularly for the first several doses and whenever the dose changes. Remember the long half-life: next-morning grogginess after a bedtime dose is common.
• Additive with alcohol and other CNS depressants: counsel explicitly.

Anticholinergic Burden (the Big One)

Dry mouth, constipation, urinary retention, blurred vision, dry eyes, tachycardia, and centrally, confusion, disorientation, and delirium, especially in older adults.

• Dry mouth: sugar-free gum/lozenges, sips of water, good dental hygiene (chronic dry mouth promotes caries).
• Constipation: hydration, fiber, and a stimulant/osmotic laxative if needed; ask about it proactively, as patients underreport it.
• Urinary retention: caution or avoid in men with BPH and in anyone with bladder-outlet obstruction; ask about hesitancy and incomplete emptying.
• Blurred vision / eye symptoms: caution or avoid in narrow-angle glaucoma (mydriatic effect can precipitate an attack).
• Confusion in the elderly: if it appears, stop the drug; do not try to manage through it. This is the Beers-list concern made real.
• The most durable management strategy is dose minimization and correct patient selection. Every anticholinergic effect scales with dose and with the patient's baseline vulnerability.

QTc Prolongation

Hydroxyzine can prolong the QT interval and, rarely, precipitate torsades de pointes. The absolute risk in a young, healthy patient on a modest dose is low, but it is real and additive.

Less Common

• Headache, dizziness.
• Paradoxical stimulation: restlessness, agitation, rarely seizures at high doses; more often seen in children.
• Hypotension (particularly with IM use) and injection-site reactions.
• Rare hypersensitivity reactions, including reports of fixed drug eruption and, very rarely, serious skin reactions.

Part 6: Overdose and Toxicity

Hydroxyzine is comparatively safe in overdose relative to older sedatives, but overdose is not benign: it is essentially an anticholinergic toxidrome plus sedation plus a cardiac-conduction concern.

Clinical Picture

• Anticholinergic toxidrome: "hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter": hyperthermia, dry flushed skin, mydriasis with blurred vision, urinary retention, ileus, tachycardia, and agitation/delirium progressing to hallucinations.
• CNS depression / oversedation, which in large ingestions or combined with other depressants can compromise the airway.
• Cardiac: QT prolongation, and in severe cases arrhythmia including torsades.
• Seizures can occur.

Management

• This is an ED evaluation. Supportive care is the mainstay: airway/breathing support, cardiac monitoring with attention to QTc, and management of hyperthermia and agitation.
• Benzodiazepines for agitation and seizures.
• Correct electrolytes; magnesium for torsades.
• Physostigmine (an anticholinesterase) is the specific antidote for pure severe anticholinergic delirium but is used selectively and with cardiac caution: a toxicology/ED decision, not an outpatient one.
• Activated charcoal has a role only in the appropriate early window per local toxicology guidance.

Part 7: Drug Interactions

Hydroxyzine has no complex CYP-inhibition profile to memorize; its interactions are pharmacodynamic and predictable: additive sedation, additive anticholinergic burden, and additive QT prolongation.

Additive CNS Depression

Alcohol, benzodiazepines, opioids, z-drugs, sedating antidepressants (mirtazapine, trazodone), gabapentinoids, other antihistamines. Combined sedation can be substantial. Counsel explicitly, especially about alcohol and about opioid co-use.

Additive Anticholinergic Burden

TCAs, low-potency and several atypical antipsychotics (e.g., clozapine, quetiapine, olanzapine), oxybutynin/tolterodine, benztropine, diphenhydramine, scopolamine, paroxetine. Stacking hydroxyzine on top of these is a common, avoidable source of confusion, constipation, urinary retention, and, in the elderly, delirium and cognitive decline. Add up the total anticholinergic load before prescribing.

Additive QT Prolongation (the Interaction to Respect Most)

Class IA/III antiarrhythmics, methadone, many antipsychotics (e.g., ziprasidone, haloperidol IV, thioridazine), certain antibiotics (macrolides, fluoroquinolones), ondansetron, other antihistamines, citalopram at higher doses. Co-prescribing hydroxyzine with these raises the torsades risk. When you cannot avoid the combination, use the lowest hydroxyzine dose, keep electrolytes normal, and consider ECG monitoring.

Enhancing factors: hypokalemia, hypomagnesemia, bradycardia, and hepatic impairment (slowed clearance) all amplify the cardiac risk.

What Hydroxyzine Does Not Do

It is not a potent CYP inhibitor or inducer, so it does not meaningfully alter the levels of most co-prescribed psychotropics, a real advantage over drugs like fluvoxamine or nefazodone.

Part 8: Special Populations

The Elderly: The Central Caution (Beers List)

Hydroxyzine appears on the AGS Beers Criteria list of potentially inappropriate medications in older adults, and for good reason: the anticholinergic burden, sedation, and fall/fracture and delirium risk make it a poor default choice in geriatric patients. Older adults also clear it more slowly (half-life about 29 h), so effects accumulate.

• Prefer alternatives for chronic anxiety in the elderly (SSRI/SNRI; buspirone for its clean cognitive and fall profile).
• If you use it at all, use the lowest dose (often 12.5–25 mg), the shortest duration, screen the QT, tally other anticholinergics, and stop at the first sign of confusion or urinary retention.

Pregnancy

Guidance has tightened. Historically hydroxyzine was used across pregnancy for anxiety, nausea, and pruritus. Note that the label carries a contraindication in early pregnancy based on animal data, and current practice generally avoids hydroxyzine in the first trimester. Large observational datasets have been broadly reassuring about major malformations, but the balance of caution favors alternatives when possible. Weigh the (usually low) severity of the anxiety indication against any fetal uncertainty: this is rarely a "must continue through pregnancy" drug the way a mood stabilizer can be.

Lactation

Hydroxyzine and its metabolites pass into breast milk, and there is a theoretical concern for infant sedation and irritability; second-generation antihistamines (loratadine, cetirizine) are generally preferred antihistamines during breastfeeding. Use hydroxyzine sparingly if at all, watch the infant for drowsiness and poor feeding, and prefer lowest effective occasional dosing over standing use.

Hepatic Impairment

Hydroxyzine is hepatically metabolized; clearance is reduced and the half-life prolonged in liver disease. Reduce the dose and lengthen the interval; the elderly effectively behave like mild hepatic-impairment patients for dosing purposes.

Renal Impairment

Less critical than hepatic, but dose reduction is prudent in significant renal impairment given accumulation of the metabolite (cetirizine is renally cleared).

Children

Used for pre-op sedation, pruritus, and occasionally anxiety, but paradoxical excitation (agitation, hallucinations, rarely seizures) is more common in children, and pediatric dosing is weight-based, a pediatric-specific decision.

Part 9: Discontinuation: The Easy Part (and a Genuine Advantage)

This is where hydroxyzine shines relative to nearly every other anxiolytic. There is no physiologic dependence, no tolerance to the anxiolytic effect that forces dose escalation, no withdrawal syndrome, and no rebound anxiety on stopping. You can discontinue it abruptly without a taper.

• No DEA schedule, no controlled-substance agreements, no urine drug screens, no diversion monitoring.
• The only caveat is behavioral, not physiologic: a patient who has relied on nightly hydroxyzine for sleep may experience a stretch of poorer sleep when they stop. This is loss of a sleep aid, not a withdrawal syndrome, and it resolves.

This freedom from dependence is, alongside its rapid onset, the entire strategic reason to reach for hydroxyzine over a benzodiazepine.

Part 10: Hydroxyzine vs the Alternatives

vs Benzodiazepines

Bottom line: for acute, PRN anxiety in a patient where dependence is the dominant concern (active or past SUD, diversion risk, a no-controlled-substances policy), hydroxyzine is the preferred fast-acting option. Benzodiazepines are more reliably potent anxiolytics, but you pay for that with the entire dependence/tolerance/withdrawal apparatus. Hydroxyzine trades that liability for an anticholinergic one, which is the better trade in the young and medically well and the worse trade in the elderly.

vs Buspirone

Bottom line: these two non-controlled anxiolytics are complementary, not competing. Buspirone is the better choice for chronic, scheduled GAD management and is dramatically safer in the elderly (no sedation, no anticholinergic load, no fall risk), but it does nothing acutely and is useless PRN. Hydroxyzine is the better choice when you need something now: a PRN dose, a bridge while an SSRI or buspirone ramps up, or a sleep aid. A common, sensible pairing: start buspirone or an SSRI for the long game and give hydroxyzine PRN for breakthrough anxiety in the interim.

The Place It Holds

Hydroxyzine is the answer to a specific clinical question: "My patient needs fast, non-addictive anxiety or sleep relief, what do I reach for?" It is not a first-line maintenance treatment for any anxiety disorder, and it is not for everyone (mind the elderly and the QT). But as a non-controlled, rapid-onset, PRN-friendly anxiolytic, it fills a gap that neither SSRIs (too slow, not PRN), buspirone (too slow, not PRN), nor benzodiazepines (too much baggage) can fill on their own.

The Bedside Cheat Sheet